Blincyo (Blinatumomab) for Injection 35 mcg/vial

Manufacturer
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
 
Contents
Blinatumomab
 
Indication
Minimal residual disease (MRD) +ve, relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
 
Instruction
Single cycle treatment: Continuous IV infusion for 28 days followed by 14-day treatment-free interval. MRD +ve B-cell precursor ALL Patient ≥45 kg Cycle 1 (fixed-dose): 28 mcg daily on days 1-28. Consolidation cycles: 28 mcg daily on days 1-28. Premed Adult Prednisone 100 mg IV or equiv (eg, dexamethasone 16 mg) 1 hr prior to 1st dose in each cycle. Relapse or refractory B-cell precursor ALL Patient ≥45 kg Cycle 1 (fixed-dose): Initially 9 mcg daily on days 1-7 then 28 mcg daily on days 8-28. Consolidation cycles: 28 mcg daily on days 1-28. Patient <45 kg Cycle 1 (BSA-based dose): Initially 5 mcg/m² daily (not to exceed 9 mcg daily) on days 1-7 then 15 mcg/m² daily (not to exceed 28 mcg daily) on days 8-28. Consolidation cycles: 15 mcg/m² daily (not to exceed 28 mcg daily) on days 1-28. Premed Adult Dexamethasone 20 mg 1 hr prior to 1st dose of each cycle prior to step dose (eg, cycle 1 day 8) & when restarting after ≥4 hr interruption. Ped Dexamethasone 5 mg/m² up to max: 20 mg prior to 1st dose in 1st cycle prior to step dose (eg, cycle 1 day 8) & when restarting after ≥4 hr interruption in 1st cycle.
 
Drug interaction
Monitor for toxicity (eg, warfarin) or drug conc (eg, cyclosporine) w/ CYP450 substrates.